185122-74-1

Basic information

• Product Name: 1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDRO-
• Synonyms: 5-BROMO-INDAN-1-YLAMINE;5-BROMO-2,3-DIHYDRO-1H-INDEN-1-AMINE;1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDRO-;5-BROMO-2,3-DIHYDRO-1H-INDEN-1-AMINE HYDROCHLORIDE
• CAS NO: 185122-74-1
• Molecular Formula: C₉H₁₀BrN
• Molecular Weight: 212.09
• Mol File: 185122-74-1.mol

Chemical Properties

• Boiling Point: 278.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.490±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.05±0.20(Predicted)
• CAS DataBase Reference: 1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDRO-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDRO-(185122-74-1)
• EPA Substance Registry System: 1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDRO-(185122-74-1)

Safety Data

• Hazardous Substances Data: 185122-74-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDROis used as a building block in organic synthesis for the creation of various complex organic molecules. Its unique structure, including the bromine atom and dihydrogroup, allows for versatile chemical reactions and modifications, making it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDROis used as a starting material or intermediate in the development of new drugs. Its chemical properties, such as the presence of an amine group and a bromine atom, can be exploited to design and synthesize novel drug candidates with potential therapeutic applications. Further research is needed to explore its potential as a pharmaceutical agent and to optimize its pharmacological properties.
Used in Material Science:
1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDROmay also find applications in material science, particularly in the development of new materials with unique properties. Its chemical structure, including the aromatic ring and bromine atom, could contribute to the creation of materials with specific electronic, optical, or mechanical properties. Further investigation is required to determine its suitability and potential applications in this field.

Upstream product

• 1251457-83-6 5-bromo-indan-1-one oxime 
• 34598-49-7 5-Bromo-1-indanone 
• 34598-50-0 5-bromo-1-indanol 
• 158330-91-7 5-bromo-1-chloro-indane 
• 185122-63-8 5-bromo-2,3-dihydro-1H-inden-1-one oxime 
• 701268-37-3 1-azido-5-bromo-2,3-dihydro-1H-indene 

Downstream Products

• 903557-29-9 (S)-5-bromoindan-1-ylamine 
• 1299483-37-6 tert-butyl {5-[(1E)-3-oxo-3-({2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]ethyl}amino)prop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}carbamate 
• 1299483-38-7 (2E)-3-(1-Amino-2,3-dihydro-1H-inden-5-yl)-N-{2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]-ethyl}acrylamide 
• 1299482-89-5 (2E)-3-(1-Acetamido-2,3-dihydro-1H-inden-5-yl)-N-{2,2,2-trifluoro-1-[3-(trifluoromethyl)-phenyl]ethyl}acrylamide 
• 1199829-00-9 benzyl 5-(hydroxymethyl)-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1251457-86-9 benzyl 5-(chloromethyl)-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1199828-99-3 methyl 1-(benzyloxycarbonylamino)-2,3-dihydro-1H-indene-5-carboxylate 
• 1199829-04-3 benzyl 5-((4-(hydroxymethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1199828-95-9 N-(5-((4-(hydroxymethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)-2,3-dihydro-1H-inden-1-yl)-2-methoxybenzenesulfonamide 
• 1199829-02-1 ethyl 1-((1-(benzyloxycarbonylamino)-2,3-dihydro-1H-inden-5-yl)methyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 

Relevant articles and documents

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

Hypercontractility of the cardiac sarcomere may be essential for the underlying pathological hypertrophy and fibrosis in genetic hypertrophic cardiomyopathies. Aficamten (CK-274) is a novel cardiac myosin inhibitor that was discovered from the optimization of indoline compound 1. The important advancement of the optimization was discovery of an Indane analogue (12) with a less restrictive structure-activity relationship that allowed for the rapid improvement of drug-like properties. Aficamten was designed to provide a predicted human half-life (t1/2) appropriate for once a day (qd) dosing, to reach steady state within two weeks, to have no substantial cytochrome P450 induction or inhibition, and to have a wide therapeutic window in vivo with a clear pharmacokinetic/pharmacodynamic relationship. In a phase I clinical trial, aficamten demonstrated a human t1/2 similar to predictions and was able to reach steady state concentration within the desired two-week window.

Deconstructive Oxygenation of Unstrained Cycloalkanamines

A deconstructive oxygenation of unstrained primary cycloalkanamines has been developed for the first time using an auto-oxidative aromatization promoted C(sp3)?C(sp3) bond cleavage strategy. This metal-free method involves the substitution reaction of cycloalkanamines with hydrazonyl chlorides and subsequent auto-oxidative annulation to in situ generate pre-aromatics, followed by N-radical-promoted ring-opening and further oxygenation by 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) and m-cholorperoxybenzoic acid (mCPBA). Consequently, a series of 1,2,4-triazole-containing acyclic carbonyl compounds were efficiently produced. This protocol features a one-pot operation, mild reaction conditions, high regioselectivity and ring-opening efficiency, broad substrate scope, and is compatible with alkaloids, osamines, and peptides, as well as steroids.

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME

The compounds represented by Formula (I), which are peripheral alkyl and alkenyl chains extended benzene derivatives, are useful as dual autotaxin (ATX) / histone deacetylase (HD AC) inhibitors. These compounds may be included in a pharmaceutical composition along with a pharmaceutically acceptable carrier, and be used in a therapeutically effective amount for prophylaxis or treatment of various diseases and disorders.

DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS

Provided are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt, thereof for use in methods of treatment heart diseases through cardiac sarcomere inhibtion.

Substituent effects on chiral resolutions of derivatized 1-phenylalkylamines by heptakis(2,3-di-O-methyl-6-O-tert-butyldimethylsilyl)-β-cyclodextrin GC stationary phase

Chiral resolutions of trifluoroacetyl-derivatized 1-phenylalkylamines with different type and position of substituent were investigated by capillary gas chromatography by using heptakis(2,3-di-O-methyl-6-O-tert-butyldimethylsilyl)-β-cyclodextrin diluted in OV-1701 as a chiral stationary phase. The influence of column temperature on retention and enantioselectivity was examined. All enantiomers of meta-substituted analytes as well as fluoro-substituted analytes could be resolved. Temperature had a favorable influence on enantioselectivity for small amines with substituents at the ortho-position. The type of substituent at the stereogenic center of amines also had a crucial effect as the ethyl group led to poor enantioseparation. Among all analytes studied, trifluoroacetyl-derivatized 1-(2′-fluorophenyl)ethylamine exhibited baseline resolution with the shortest analysis time.

ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

A compound of formula (I): wherein the substituents are as defined in the description. Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.

Substituted ring compound and its method and use thereof

The invention provides a substituted cyclic compound as well as a use method and application thereof. The compound is a compound as shown in a formula (I) or stereoisomers, stereomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as shown in the formula (I). The invention further provides a medicament composition containing the compound. The compound and the medicament composition are capable of regulating the activity of protein kinase in a biological sample body and are used for protecting, treating or relieving proliferative diseases of patients. The formula (I) is as shown in the specification.

SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Structure based evolution of a novel series of positive modulators of the AMPA receptor

Starting from compound 1, we utilized biostructural data to successfully evolve an existing series into a new chemotype with a promising overall profile, exemplified by 19.